Key result
Nonpharmacological and targeted medical therapies improve orthostatic hypotension symptoms, but long-term outcome data remain limited.
Why the study?
Orthostatic hypotension is prevalent, causes significant morbidity and mortality, and lacks robust efficacy and safety evidence for management therapies.
What is the optimal approach to the diagnosis and management of orthostatic hypotension?
What is the optimal approach to the diagnosis and management of orthostatic hypotension?
A multidisciplinary, individualized approach combining patient education, nonpharmacological maneuvers, and tailored pharmacotherapy is crucial for managing orthostatic hypotension, highlighting the need for higher-quality clinical trials.
Answers are grounded in this paper and cite their sources.
Supports individualized nonpharmacological and pharmacological strategies for orthostatic hypotension symptom relief; leaves open confirmation in long-term randomized trials.
Orthostatic hypotension is a prevalent clinical condition, caused by heterogenous etiologies and associated with significant morbidity and mortality. Management is particularly challenging in patients with uncontrolled hypertension. A thorough assessment is needed to draw an appropriate management plan. The treatment aims to improve postural symptoms while minimizing side effects and reducing iatrogenic exacerbation of supine hypertension. A personalized management plan including rationalizing medications, patient education, identification, and avoidance of triggers, as well as nonpharmacological therapies such as compression devices, dietary modifications, and postural aids, make the first steps. Among pharmacological therapies, midodrine and fludrocortisone are the most prescribed and best studied; pyridostigmine, atomoxetine, and droxidopa are considered next. Yohimbine remains an investigational agent. A multidisciplinary team may be required in some patients with multiple comorbidities and polypharmacy. However, there is a lack of robust efficacy and safety evidence for all therapies. Building robust real-world and stratified clinical trials based on underlying pathophysiology may pave the way for further drug development and better clinical strategies and in this challenging unmet medical need.
No takes yet. Share an insight, caveat, or question.
Kulkarni et al. (2024) conducted a review in Orthostatic hypotension. Management strategies (pharmacological and nonpharmacological) was evaluated. Management of orthostatic hypotension with nonpharmacological therapies and agents like midodrine or fludrocortisone improves symptoms, though robust long-term evidence remains lacking.
Synapse has enriched 10 related papers. Consider them for comparative context: